Published in:
01-03-2020 | Prostate Cancer | Correction
Correction to: Evidence-based approach to active surveillance of prostate cancer
Published in: World Journal of Urology | Issue 3/2020
Login to get accessExcerpt
In the original publication of the article, the values in the columns “Gleason Score” and “Clinical Stage” under the section Urologic Organization Guidelines were incorrect in Table 1. Now, the values have been exchanged from their incorrect position to their correct position, and the correct Table 1 is given below:
Table 1
Summary of active surveillance enrollment criteria
|
Institution/urologic organization
|
Gleason score
|
PSA (ng/mL)
|
Clinical stage
|
Minimum number of cores taken at biopsy
|
Maximum number of positive cores
|
Maximum percentage of any biopsy core positive
|
|---|---|---|---|---|---|---|
|
Individual cohort criteria
|
||||||
|
University of Toronto [5]
|
≤ 3 + 3
|
≤ 10
|
T2
|
8
|
–
|
–
|
|
John Hopkins [6]
|
≤ 3 + 3
|
–
|
≤ T1c
|
12
|
2
|
50%
|
|
Prostate Cancer Research International Active Surveillance (PRIAS) Criteria [7]
|
≤ 3 + 3
|
≤ 10
|
≤ T2c
|
10
|
2
|
–
|
|
Memorial Sloan Kettering Cancer Center (MSKCC) [8]
|
≤ 3 + 3
|
< 10
|
≤ T2a
|
10
|
3
|
50%
|
|
St. Vincent’s, Australia [9]
|
≤ 3 + 3
|
< 10
|
≤ T2b
|
10
|
< 20% of total cores
|
< 30%
|
|
Canary Prostate Cancer Active Surveillance Study (PASS) [11]
|
≤ 3 + 4
|
< 20
|
≤ T2c
|
≥10
|
< 34% of total cores
|
–
|
|
Urologic organization guidelines
|
||||||
|
American Urology Association (AUA) [3]
|
≤ 3 + 3
|
≤10
|
≤ T2a
|
–
|
–
|
–
|
|
Cancer Care Ontario (CCO) [2]
|
≤ 3 + 3
|
–
|
≤ T2a
|
–
|
–
|
–
|
|
≤ 3 + 4
|
–
|
–
|
< 10% total tumor
|
|||
|
European Association of Urology (EAU) [4]
|
≤ 3 + 3
|
≤ 10
|
≤ T2a
|
–
|
–
|
–
|
|
National institute for Health and Care Excellence (NICE) [15]
|
≤ 3 + 3
|
≤ 10
|
≤ T2a
|
–
|
–
|
–
|